Growth-hormone secretagogue · Fact sheet

Hexarelin

Also known as Examorelin

Hexarelin stimulates growth hormone and can also affect other hormones. Small human experiments do not prove muscle or recovery benefits, and one sleep study found less deep sleep rather than an improvement.

Not FDA approvedEarly human evidence

What is Hexarelin?

Hexarelin is a synthetic peptide studied through the growth-hormone secretagogue pathway. It is not selective for a single hormone response under every experimental condition.

Benefits & claims

Muscle growth, recovery, and deeper sleep are common expectations. The available human studies mainly measure hormones, and some findings run against the sleep claim.

What the evidence supports

  • Acute studies document growth-hormone release, with prolactin and cortisol changes under some conditions.
  • The longer endocrine study did not find persistent overstimulation of the measured adrenal and prolactin responses; this is narrower than proving overall safety.
Research areas
  • Growth-hormone secretion
  • Pituitary-adrenal signaling
  • Sleep architecture

Dosage & frequency

Human study context

Hexarelin has short human hormone-response studies, but no established FDA-approved treatment dose for recovery, muscle gain, or cardiac health.

Human endocrine dose-response experiment

Healthy adult men

Amount
Separate experimental amounts up to 1 mcg/kg
Frequency
Acute study administrations
Route studied or labeled
Intravenous

Measured GH, prolactin and cortisol release; not a clinical recovery or anti-aging regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A GH response is a pharmacodynamic finding, not proof of durable clinical benefit.

Interactions & precautions

  • Short endocrine studies do not establish safety with other hormone treatments; repeated-use interaction data remain insufficient.

What is still unresolved

  • Repeated-use efficacy, tolerance, endocrine effects, and clinical safety remain unresolved.

Side effects & risks

  • A seven-person experiment found reduced stage-4 sleep and delta activity, with increased cortisol and other hormones.
  • Acute and repeated-exposure findings differ, so a single hormone result cannot predict long-term effects.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Acute endocrine experiments and small short-term studies demonstrate biological activity. A seven-person sleep study and a 16-week endocrine study are too limited to establish broad benefits or long-term safety.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Weight: reported experiences

Mixed account · personal report

Warmth, racing thoughts and perceived gym gains

A commenter later described warmth, an energized feeling and racing thoughts that settled, alongside a leaner appearance and somewhat greater strength. Ibutamoren was added later.

Amount, frequency, route and duration could not be confirmed for this account.

Training and combined exposure confound the reported changes. This is an unverified account in a commercially oriented community, not a measured hormone effect.

Read the original account

Approval status

Hexarelin has no FDA-approved therapeutic product. The cited endocrine experiments document historical human research, not an established approved recovery or sleep treatment.

Historical human studies; no FDA approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Clinical benefits for muscle or injury recovery
  • Long-term metabolic and endocrine safety
  • Whether effects differ across populations and products

Summary

Hexarelin has measurable hormone effects, but little evidence that those changes deliver the consumer benefits often claimed.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedHexarelin endocrine responses in humans

    Acute growth-hormone, prolactin, and cortisol response study.

  2. pubmedHexarelin and human sleep-endocrine activity

    Seven-volunteer study showing reduced deep-sleep measures.

  3. pubmedRepeated hexarelin exposure and the pituitary-adrenal axis

    16-week study; no persistent adrenal or prolactin overstimulation in the measured outcomes.

How we assess sources · Suggest a correction